Phase 1 study on the safety and efficacy of E6011, antifractalkine antibody, in patients with Crohn's disease

• Published in: Journal of gastroenterology and hepatology 2021-08, Vol.36 (8), p.2180-2186
• Main Authors: Matsuoka, Katsuyoshi, Naganuma, Makoto, Hibi, Toshifumi, Tsubouchi, Hirohito, Oketani, Kiyoshi, Katsurabara, Toshinori, Hojo, Seiichiro, Takenaka, Osamu, Kawano, Tetsu, Imai, Toshio, Kanai, Takanori
• Format: Article
• Language: English
• Subjects: Adult; Adverse events; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - pharmacokinetics; Antibodies, Monoclonal, Humanized - therapeutic use; Antirheumatic Agents - adverse effects; Antirheumatic Agents - pharmacokinetics; Antirheumatic Agents - therapeutic use; Chemokines; Clinical Gastroenterology; Crohn Disease - drug therapy; Crohn Disease - immunology; Crohn's disease; Dose-Response Relationship, Drug; E6011; Female; Fractalkine; Gastroenterology; Humans; Immunologic Tests; Leukocyte migration; leukocyte trafficking; Male; Middle Aged; Monoclonal antibodies; Patients; Pharmacodynamics; Pharmacokinetics; Remission; Rhinopharyngitis; Safety; Treatment Outcome; Tumor necrosis factor-α; Young Adult
• ISSN: 0815-9319; 1440-1746
• DOI: 10.1111/jgh.15463

Background and Aim E6011 is a humanized monoclonal antibody targeting fractalkine (FKN), a CX3C chemokine, which regulates leukocyte trafficking during inflammation. We evaluated the safety and pharmacokinetic profile of E6011 in patients with Crohn's disease (CD) and also performed preliminary pharmacodynamic (PD) and efficacy assessments. Methods This study included a 12‐week multiple ascending dose (MAD) phase (2, 5, 10, and 15 mg/kg intravenously every 2 weeks, n = 6, 8, 7, and 7, respectively) and a 40‐week Extension phase (n = 12) at the same dose as the MAD phase. Serum E6011, serum total FKN (free soluble FKN and E6011‐FKN complex) as a PD marker and CD activity index were evaluated. The primary outcome was safety assessment in the MAD phase. Results Twenty‐seven (96%) of 28 patients had previously been treated with anti‐tumor necrosis factor α agents. During the MAD phase, adverse events (AEs) occurred in 18 (64%). The most common AE was nasopharyngitis (five patients, 18%). No severe AEs occurred. Serious AEs occurred in three patients, progression of CD in two, and anemia in one. Serum E6011 concentrations increased dose‐dependently after infusion and reached a plateau around 4–6 weeks. Serum total FKN rose simultaneously. Five (18%) patients developed anti‐E6011 antibodies during the study. Overall, clinical response and clinical remission were observed at Week 12 in 40% (10/25) and 16% (4/25) of active CD patients, respectively. Conclusion E6011 was well‐tolerated and might be effective in CD patients. These findings need to be clarified in a randomized controlled study.